Since July 2020, infants with systemic hypertension and concern for LV diastolic dysfunction at our institution have received treatment with a long-acting ACE inhibitor, enalapril, according to a standardized protocol and strict serial Targeted Neonatal Echocardiography (TnECHO) monitoring. The gene discussed is ACE; the disease is Hypertension.